Published in:
Open Access
01-12-2020 | Imipenem | Case report
Pulmonary disease caused by a newly identified mycobacterium: Mycolicibacterium toneyamachuris: a case report
Authors:
Tomoki Kuge, Kiyoharu Fukushima, Yuki Matsumoto, Yuko Abe, Eri Akiba, Kako Haduki, Haruko Saito, Tadayoshi Nitta, Akira Kawano, Takahiro Kawasaki, Takanori Matsuki, Hiroyuki Kagawa, Daisuke Motooka, Kazuyuki Tsujino, Mari Miki, Keisuke Miki, Seigo Kitada, Shota Nakamura, Tetsuya Iida, Hiroshi Kida
Published in:
BMC Infectious Diseases
|
Issue 1/2020
Login to get access
Abstract
Background
Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is becoming a significant health burden. Recent advances in analysis techniques have allowed the accurate identification of previously unknown NTM species. Here, we report a case of NTM-PD caused by a newly identified mycobacteria in an immunocompetent patient.
Case presentation
A 44-year-old woman was referred to our hospital due to the frequent aggravation of her chronic respiratory symptoms, with NTM-PD-compatible computed tomography findings. Unidentified mycobacterium was repeatedly isolated from respiratory specimens and we diagnosed her as NTM-PD of unidentified mycobacterium. Subsequent whole-genome analysis revealed that the unidentified mycobacterium was a novel mycobacterium genetically close to Mycolicibacterium mucogenicum. We started combination therapy with clarithromycin, moxifloxacin, amikacin, and imipenem/cilastatin, referring to drug sensitivity test results and observed its effect on M. mucogenicum infection. Her symptoms and radiological findings improved significantly.
Conclusion
We report a case of NTM-PD caused by a newly identified mycobacteria, Mycolicibacterium toneyamachuris, genetically close to M. mucogenicum. This pathogenic mycobacterium showed different characteristics from M. mucogenicum about clinical presentation and drug sensitivity. The clinical application of genomic sequencing will advance the identification and classification of pathogenic NTM species, and enhance our understanding of mycobacterial diseases.